Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels

Journal of Clinical Lipidology

Volumn 6, Issue 5, 2012, Pages 434-442

  Querton, Laurent ^a   Buysschaert, Martin ^a   Hermans, Michel P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Atherogenic dyslipidemia; Diabetes; LDL C; Non HDL C; Statins; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VASCULAR DISEASE; WAIST CIRCUMFERENCE;

EID: 84866738927     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2012.04.002     Document Type: Article

References (57)

1. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
2. J.D. Brunzell, M. Davidson, and C.D. Furberg Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
3. J.-C. Fruchart, F. Sacks, M.P. Hermans for the Residual Risk Reduction Initiative The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 Suppl 2008 1 34
4. 3i) Diab Vasc Dis Res 5 2008 319 335
5. P. Gaede, H. Lund-Andersen, and H.H. Parving Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
6. American Diabetes Association Clinical practice recommendations 2010 Diabetes Care 33 2010 S1 S100
7. M.P. Hermans, and J.C. Fruchart Reducing residual vascular risk in patients with atherogenic dyslipidaemia: where do we go from here? Clin Lipidol 5 2010 811 826
8. F. Nobels, N. Debacker, C. Brotons for the OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) International Steering Committee Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus Cardiovasc Diabetol 10 2011 82
9. M.P. Hermans, S.A. Ahn, and M.F. Rousseau Residual vascular risk in T2DM: the next frontier M.B. Zimering, Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications 2011 Intech Rijeka, Croatia 45 66
10. S.M. Haffner, S. Lehto, and T. Rönnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
11. A. Juutilainen, S. Lehto, and T. Rönnemaa Type 2 diabetes as a 'coronary heart disease equivalent.' An 18-year prospective population-based study in Finnish subjects Diabetes Care 28 2005 2901 2907
12. A.E. Buyken, A. von Eckardstein, and H. Schulte Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study Eur J Cardiovasc Prev Rehabil 14 2007 230 236
13. T.K. Schramm, G.H. Gislason, and L. Kober Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people Circulation 117 2008 1945 1954
14. G. Brown, J.J. Albers, and L.D. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
15. J.C. LaRosa, S.M. Grundy, and D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
16. J. Shepherd, P. Barter, R. Carmena for the Treating to New Targets Investigators Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study Diabetes Care 29 2006 1220 1226
17. P. Barter, A.M. Gotto, and J.C. LaRosa Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
18. V.E. Friedewald Jr., C.M. Ballantyne, and M.H. Davidson The editor's roundtable: lipid management beyond statins - reducing residual cardiovascular risk Am J Cardiol 102 2008 559 567
19. P.H. Jones Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering Am J Cardiol 102 2008 41L-7L
20. K.G. Alberti, R.H. Eckel, S.M. Grundy International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
21. Th Munoko, and M.P. Hermans Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort Diab Met Syndr 2 2008 115 124
22. F. Dehout, S. Haumont, and N. Gaham Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction: prevalence, gender differences and HOMA-hyperbolic product Diab Metab Syndr 2 2008 5 11
23. V. Kothari, R.J. Stevens, and A.I. Adler UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine Stroke 33 2002 1776 1781
24. R.J. Stevens, R.L. Coleman, and A.I. Adler UKPDS 66: risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes Diabetes Care 27 2004 201 207
25. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
26. M.P. Hermans, S.A. Ahn, and M.F. Rousseau Log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males Cardiovasc Diabetol 9 2010 88
27. A.S. Levey, J.P. Bosch, and J.B. Lewis A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
28. J. Ferrieres, E. Tocque-Le Gousse on behalf of the French CEPHEUS investigators Assessment of lipid-lowering treatment in France Arch Cardiovasc Dis 101 2008 557 563
29. M.P. Hermans, M. Castro Cabezas, and T. Strandberg Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries Curr Med Res Opin 26 2010 445 454
30. J.R. Guyton, D.J. Betteridge, and M. Farnier Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes Diab Vasc Dis Res 8 2011 160 172
31. Fruchart JC. PCSK9: the functional relevance of fenofibrate-statin combination therapy to reduce residual cardiovascular risk. Int J Diab Mellitus., in press.
32. R.A. Davis Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver Biochim Biophys Acta 1440 1999 1 31
33. J.C. Fruchart, and P. Duriez HDL and triglyceride as therapeutic targets Curr Opin Lipidol 13 2002 605 616
34. W.T. Garvey, S. Kwon, and D. Zheng Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance Diabetes 52 2003 453 462
35. M. Adiels, S.-O. Olofsson, and M.-R. Taskinen Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome Arterioscler Thromb Vasc Biol 28 2008 1225 1236
36. V.J. Carey, L. Bishop, and N. Laranjo Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control Am J Cardiol 106 2010 757 763
37. J.-C. Fruchart, F.M. Sacks, and M.P. Hermans Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R3i) Curr Med Res Opin 26 2010 1793 1797
38. D.A. Blasiole, R.A. Davis, and A.D. Attie The physiological and molecular regulation of lipoprotein assembly and secretion Mol Biosyst 3 2007 608 619
39. G. Assmann, P. Cullen, and H. Schulte Non-LDL-related dyslipidemia and coronary risk: a case-control study Diab Vasc Dis Res 7 2010 204 212
40. C.M. Ballantyne, J.S. Raichlen, and V.A. Cain Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial J Am Coll Cardiol 52 2008 626 632
41. A.D. Sniderman Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidol 2 2008 36 42
42. H. Bays, S. Conard, and L.A. Leiter Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis 9 2010 136
43. M. Farnier, W. Taggart, and Q. Dong Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients J Clin Lipidol 5 2011 179 187
44. 100 measurement in diabetes: Discriminant Ratio and unbiased equivalence Cardiovasc Diabetol 10 2011 20
45. P.L. Libby The forgotten majority. Unfinished business in cardiovascular risk reduction J Am Coll Cardiol 46 2005 1225 1228
46. A.D. Sniderman Apolipoprotein B versus non-high-density lipoprotein cholesterol. And the winner is... Circulation 112 2005 3366 3367
47. S. Kathiresan, J.D. Otvos, and L.M. Sullivan Increased small low-density lipoprotein particle number. A prominent feature of the metabolic syndrome in the Framingham Heart Study Circulation 113 2006 20 29
48. M.P. Hermans, S.A. Ahn, and M.F. Rousseau The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: Comparison with reference lipid markers Diab Metab Syndr 1 2007 23 28
49. D. Sulkes, B.G. Brown, and R.M. Krauss The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk Am J Cardiol 101 2008 828 842
50. M.A. Denke Weighing in before the fight. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus Apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy Circulation 112 2005 3368 3370
51. ACCORD Study Group H.N. Ginsberg, M.B. Elam, and L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
52. M.P. Hermans Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD Diab Vasc Dis Res 8 2011 180 189
53. J.S. Volek, M.L. Fernandez, R.D. Feinman, and S.D. Phinney Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome Prog Lipid Res 47 2008 307 318
54. H.I. Katcher, A.M. Hill, J.L. Lanford, J.S. Yoo, and P.M. Kris-Etherton Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol Endocrinol Metab Clin North Am 38 2009 45 78
55. R.S. Rosenson Management of non-high-density lipoprotein abnormalities Atherosclerosis 207 2009 328 335
56. R.S. Rosenson, M.H. Davidson, and R. Pourfarzib Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk Atherosclerosis 213 2010 1 7
57. M.P. Hermans, and J.C. Fruchart Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians Ther Adv Chronic Dis 2 2011 307 323